QUEBEC CITY, June 22, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will be presenting at the 2011 BIO Business Forum during the annual BIO International Convention. Mr. Driscoll's presentation will be given in the Georgetown Room of the Walter E. Washington Convention Center in Washington, DC on Wednesday, June 29, 2011 at 2:15 p.m. EDT. The presentation will include an overview of the company's nictonic acetylcholine receptor technology, with emphasis on the lead development program for the treatment of asthma, ASM-024.
About Asmacure Ltee
Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases. The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma. ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication. Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.
Asmacure is a privately held company located in Quebec City, Canada. The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec. For more information visit www.asmacure.com
Tiberend Strategic Advisors, Inc.
Andrew Mielach, email@example.com
Claire Sojda, firstname.lastname@example.org
SOURCE Asmacure Ltee